Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05287126 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
A Phase 2 study of Ulcerative Colitis, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 20
- Study locations
NCT05287126: Recruiting Phase 2 study of Ulcerative Colitis, sponsored by Pfizer.
NCT05287126 is a Phase 2 study of Ulcerative Colitis that is actively recruiting participants, run by Pfizer. The registered enrollment target is 36 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05287126, a Phase 2 study of Ulcerative Colitis, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in adolescents (≥ 12 years up to \< 18 years of age). Participants who will complete the total 52-week treatment period will have the opportunity to continue in a Long-Term Extension (LTE) Period of up to 4 years (5 years after study enrollment).
Conditions Studied
Interventions
- DRUG Etrasimod
Study Locations (20)
California
- Valley View Wellness Medical Center - Garden Grove
- Loma Linda Children's Hospital - Loma Linda
- Loma Linda University Clinical Trial Center - Loma Linda
- Loma Linda University Eye Institute - Loma Linda
- Loma Linda University Medical Center - Loma Linda
- Loma Linda University Pediatric Clinics - Loma Linda
- Loma Linda University Children's Hospital Pediatric Specialty Clinics - San Bernardino
- University of California San Francisco, - San Francisco
- University of California San Francisco - San Francisco
- University of California,San Francisco Pediatric ClinicalResearch Center (PCRC) - San Francisco
Arkansas
- Arkansas Children's (IP Address) - Little Rock
- Arkansas Children's - Little Rock
Michigan
- William Beaumont Hospitals Reference Laboratory - Royal Oak
- William Beaumont Hospital - Royal Oak
Ohio
- University Hospitals Cleveland Medical Center Rainbow Babies & Children's Hospital - Cleveland
- University Hospitals Cleveland Medical Center - Cleveland
Florida
- Arnold Palmer Hospital - Center for Digestive Health and Nutrition - Orlando
Illinois
- University of Chicago Medical Center - Chicago
Massachusetts
- Boston Children's Hospital - Boston
Texas
- Advance Clinical Trial PLLC - Abilene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-12-16 |
| Est. Completion | 2031-08-07 |
| Phase | Phase 2 |
What NCT05287126 shows while recruiting
NCT05287126 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 1 intervention - of which Etrasimod is the first listed.
NCT05287126 names 20 study sites across 8 states, led by California, Arkansas, Michigan.
Frequently Asked Questions
What is clinical trial NCT05287126 about?
NCT05287126 is a clinical study titled "A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis". The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in adolescents (≥ 12 years up to \< 18 years of age). Participants who will complete the total 52-week treatment period will ha...
What is the current status of trial NCT05287126?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2022-12-16. Estimated completion is 2031-08-07.
What conditions does trial NCT05287126 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT05287126?
The interventions under investigation include: Etrasimod (DRUG).
Who is sponsoring clinical trial NCT05287126?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05287126 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05287126's enrollment target sits among peer trials
36 98th of 122 higher than 24 of 122 other Ulcerative Colitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
RECRUITING · Phase 2
-
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
Treatment of UC With Novel Therapeutics
RECRUITING · Phase 2
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI